AllianceBernstein
ARQT icon

AllianceBernstein’s Arcutis Biotherapeutics ARQT Stock Holding History

AllianceBernstein’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Buy
136,393
+18,170
+15% +$423K ﹤0.01% 1788
2026
Q1 		$3.43M Buy
118,223
+1,863
+2% +$47.5K ﹤0.01% 1718
2025
Q4 		$3.38M Buy
116,360
+3,000
+3% +$76.8K ﹤0.01% 1731
2025
Q3 		$2.14M Hold
113,360
– – ﹤0.01% 1969
2025
Q2 		$1.59M Hold
113,360
– – ﹤0.01% 2049
2025
Q1 		$1.77M Buy
113,360
+2,200
+2% +$31K ﹤0.01% 1971
2024
Q4 		$1.55M Hold
111,160
– – ﹤0.01% 2100
2024
Q3 		$1.03M Hold
111,160
– – ﹤0.01% 2312
2024
Q2 		$1.03M Buy
111,160
+36,460
+49% +$330K ﹤0.01% 2284
2024
Q1 		$740K Buy
74,700
+7,440
+11% +$55.5K ﹤0.01% 2413
2023
Q4 		$217K Sell
67,260
-5,100
-7% -$13.9K ﹤0.01% 2955
2023
Q3 		$384K Sell
72,360
-7,670
-10% -$65.2K ﹤0.01% 2709
2023
Q2 		$763K Sell
80,030
-68,470
-46% -$760K ﹤0.01% 2424
2023
Q1 		$1.63M Buy
148,500
+110,000
+286% +$1.59M ﹤0.01% 1991
2022
Q4 		$570K Buy
38,500
+10,200
+36% +$178K ﹤0.01% 2559
2022
Q3 		$541K Hold
28,300
– – ﹤0.01% 2608
2022
Q2 		$603K Buy
28,300
+8,000
+39% +$164K ﹤0.01% 2598
2022
Q1 		$391K Hold
20,300
– – ﹤0.01% 2772
2021
Q4 		$421K Buy
20,300
+1,500
+8% +$29.9K ﹤0.01% 2809
2021
Q3 		$449K Hold
18,800
– – ﹤0.01% 2796
2021
Q2 		$513K Buy
18,800
+5,100
+37% +$144K ﹤0.01% 2797
2021
Q1 		$396K Sell
13,700
-2,100
-13% -$65.6K ﹤0.01% 2775
2020
Q4 		$444K Sell
15,800
-59,864
-79% -$1.47M ﹤0.01% 2647
2020
Q3 		$2.22M Sell
75,664
-1,700
-2% -$45.4K ﹤0.01% 1795
2020
Q2 		$2.34M Buy
77,364
+8,528
+12% +$246K ﹤0.01% 1757
2020
Q1 		$2.05M Buy
+68,836
New +$1.85M ﹤0.01% 1657

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AllianceBernstein's ARQT Position: Q2 2026 in Review

AllianceBernstein increased its Arcutis Biotherapeutics (ARQT) stake by 15% in Q2 2026, buying an estimated $423K and bringing the position to 136,393 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1788.

AllianceBernstein first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $3.43M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • AllianceBernstein held 136,393 shares of Arcutis Biotherapeutics worth $3.21M as of Q2 2026.
  • AllianceBernstein bought 18,170 Arcutis Biotherapeutics shares in Q2 2026, an estimated $423K.
  • Arcutis Biotherapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1788 holding.
  • AllianceBernstein first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • AllianceBernstein's Arcutis Biotherapeutics position peaked at $3.43M in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.